We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

New treatment

8 February 2017 By Neil Unmack

Departing chief Andrew Witty’s final results beat expectations. He steered the drug giant through scandal and patent losses, but did smart deals, and created value. His vision of a diversified group is still unfinished, though, leaving successor Emma Walmsley plenty to do.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)